Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010
Oct 1, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of ADVAIR DISKUS® (Fluticasone... More |
Sep 27, 2019 Lannett Company, Inc. (NYSE: LCI) ("Lannett" or the "Company") today announced the closing of $86.25 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the "Notes") in... More |
Sep 25, 2019 Lannett Company, Inc. (NYSE: LCI) ("Lannett" or the "Company") today announced the pricing of $75 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the "Notes") in a... More |
Sep 24, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it intends to offer, subject to market conditions and other factors, $75 million aggregate principal amount of convertible senior notes due... More |
Aug 28, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Sinotherapeutics Inc., a China-based specialty pharmaceutical company, to be the exclusive U.S.... More |
Fiscal 2019 Fourth Quarter Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 fourth quarter and full year ended June 30, 2019. "In fiscal 2019, we made excellent progress rebuilding our... More |
Aug 27, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a three-year advisory services agreement with its strategic alliance partner, Cediprof, Inc., a wholly owned subsidiary... More |
Aug 20, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 fourth quarter and full year on Tuesday, August 27, 2019, after the market closes.... More |
Aug 1, 2019 Lannett Company, Inc. (NYSE: LCI) today announced the appointment of John Kozlowski as chief financial officer (CFO), effective August 31, 2019. He succeeds Martin Galvan, who, as previously... More |
Jul 8, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a future exclusive supply and distribution agreement for the approved Levothyroxine Sodium Tablets USP of Cediprof, Inc.,... More |